Emergent Health Corp. (EMGE:OTC Markets) Announces Overall Corporate Sales Progress And Emergent Medical Foods Subsidiary Success Path Plus Capital Raise

KING OF PRUSSIA, PA / ACCESSWIRE / August 4, 2020 / Emergent Health Corp. (the “Company”) (OTC PINK:EMGE) purpose of this Press Release is to further update our shareholders on the Company’s overall business.

The Company views one of the most exciting parts of its business in the area of Emergent Medical Foods, Inc. (the “Subsidiary). It is the Subsidiary that is launching CancX Nutritional Support for Cancer patients as well as Anxium, an all-natural patent pending stress relief product designed to compete with drugs like Valium, Xanax, Klonepin, Vistaril and other prescription drugs. The Subsidiary previously reported the positive results obtained by Cancer patients in a press release in May 2020.

The Subsidiary has also retained a successful social network marketing firm to market CancX Nutritional Support. Results are expected to materialize over the next 6 months.

In addition the Subsidiary has completed a $100,000 seed capital raise in the past year and is financially stable. The next expected step for the Subsidiary is to obtain up to $1,000,000 from Advisory Physicians with units of $5,000 minimum at $0.25 per share and a target of 100 to 200 Physicians. The Subsidiary believes this will set the stage for Physician recommendation of all of its products.

The expected goal of the Subsidiary is to go public in three years with an IPO at a target of $6.00 per share. These efforts are expected to increase the value of the parent Company too.

The Company officially launched its new networking website in the first half of 2020. Consolidated sales were $80,266.29. Total current cash assets and inventory are in excess of $300,000. We expect investors to realize we are under total reconstruction from prior management which left the Company with literally no business or cash in 2016 after the Company had generated over $5,000,000 in sales over a prior period of a few years. The Company expects to do this and more as its patented adult stem cell stimulators combined with a multi vitamin literally have no known competition to the best of its knowledge. The Company is confident in its new judicious beginning as none of its key people draw a salary other than the Office Manager.

Company operations produced a modest loss and at same time still leave the Company well capitalized to move forward. The goal of the Company is to double the first half sales in the second half of the year.

In addition, the Company is in the process of a $250,000 capital raise. The objective of this capital raise is to:

1. Become current with OTC Markets
2. Have an audit
3. Move up to OTCQB
4. Model the network marketing plan more like Herbal Life (HLF) which has over 2,000,000 distributors and now trades over $50 per share.
5. To hire more key management to grow the Company and its Subsidiary

The Company, through an Agent, has at this time purchased 140,000 free trading shares of its current free trading shares of 2,120,594 shares in CEDE (Street Name) with the intent to retire those shares to Treasury stock. The remaining 58,101,101 shares which are not in Street Name are not eligible for conversion to Street Name until the Company has Current Information posted at OTC Markets. At such time the Company is considering working with its shareholders to establish some kind of registered liquidity event if and when the market becomes more liquid, and if feasible.

The Company also reiterates the belief it has discovered that up to 20,000,000 of its shares may have been issued by past management without proper payment for shares. A Restraining Order has been issued by the Court in Monmouth County, New Jersey to stop legend removal or transfer of those shares by the Transfer Agent unless the shareholders can prove they paid for stock.

The Company intends to continue to work diligently towards current status on OTC Markets as outlined above.

All of the above can be considered forward looking statements.

The Company continues with no debt and sufficient operating capital.

Nothing in this press release has been reviewed by the Food & Drug Administration. Products mentioned are not intended to diagnose, treat, prevent or cure any disease.

The Company hopes shareholders will find this Press Release informative as to its intentions.

About Emergent Health Corp.:

Emergent Health Corp., a diversified biotechnology firm, is focused on the health and wellness industry. With patented, patent pending and proprietary nutritionally designed products, Emergent believes it is positioning itself as a leader in the fields of Regenerative Medicine and/or Health as defined by the National Institute of Health

This press release contains certain “forward-looking” statements, defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are estimates reflecting the company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors that could cause actual results to differ materially from those estimated by the company.

This press release is provided for information purposes only and is not intended to constitute an offer to sell or a solicitation of an offer to buy securities.

CONTACT:

Emergent Health Corp.
Investor Relations
484-518-9000

SOURCE: Emergent Health Corp

View source version on accesswire.com:
https://www.accesswire.com/600077/Emergent-Health-Corp-EMGEOTC-Markets-Announces-Overall-Corporate-Sales-Progress-And-Emergent-Medical-Foods-Subsidiary-Success-Path-Plus-Capital-Raise